|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,180,582: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,180,582, granted on February 26, 1980, to Hoffmann-La Roche Inc., covers a class of beta-lactam antibiotics, specifically carbapenem derivatives, notably imipenem and its intermediates. The patent's scope extends to the composition, synthesis, and use of these compounds for antibacterial activity, significantly influencing the development and commercialization of carbapenem antibiotics. This analysis dissects its claims, scope, and impact on the intellectual property landscape, providing a comprehensive understanding essential for pharmaceutical stakeholders.
What is the scope of U.S. Patent 4,180,582?
Key Elements
- Chemical compounds protected: Primarily covers the chemical class of carbapenem derivatives, including imipenem.
- Claims encompass: Composition of matter, synthesis methods, intermediate compounds, and their therapeutic use.
- Therapeutic application: Induces antibacterial effects, especially against resistant bacteria.
- Generality: Broader claims extend to various 4-methylcarbapenem derivatives with specific substituents.
Patent Classification
- Primary CPC Class: A61K (Preparations for medical, dental, or hygienic purposes), specifically subclasses pertaining to antibiotics.
- USPC Class: 514/712 (Antibiotic compounds).
Scope Note
The patent aimed to secure intellectual property over novel carbapenem compounds with enhanced stability and antibacterial potency, including methods of synthesis and their application, thereby establishing foundational IP for later carbapenem antibiotics.
What are the specific claims of U.S. Patent 4,180,582?
Claim Breakdown
| Claim Number |
Description |
Scope |
| Claim 1 |
A compound characterized by a specific carbapenem structure with particular substituents at the 2-, 3-, and 4-positions |
Broad, covering imipenem and close derivatives |
| Claim 2 |
A process for preparing the compound claimed in Claim 1, involving specific chemical reactions |
Synthesis method patent, enabling production |
| Claim 3 |
Intermediate compounds used in the synthesis |
Secures rights over precursor molecules |
| Claims 4–7 |
Pharmaceutical compositions containing the compound |
Protects formulations and medicinal use |
Key Features of Claims
- Structural breadth: Claims include compounds with carbapenem core structures with modifications at various positions.
- Method claims: Cover synthesis pathways, including hydrolysis, acylation, and substitution reactions.
- Use claims: Encompass methods of treating bacterial infections with the claimed compounds.
- Intermediate and derivative claims: Secure rights over precursor molecules and analogues with similar activity.
Implications
The claims' breadth ensured comprehensive protection for imipenem and related derivatives, incentivizing research and commercial implementation by preventing immediate generic or biosimilar competition.
What does the patent landscape look like for U.S. Patent 4,180,582?
Historical Context (Pre- and Post-Grant)
- Pre-generic landscape: The patent provided a monopoly on imipenem until its expiration in 1997.
- Post-expiration: Patent expiry opened up markets for generic manufacturers, prompting multiple biosimilar and generic entries.
- Citations and citing patents: The patent has been both heavily cited and has cited numerous subsequent patents, influencing subsequent carbapenem development.
Overlap and Contemporaneous Patents
| Patent Number |
Applicant |
Focus |
Grant Date |
Overlap with 4,180,582 |
| 4,347,201 |
Hoechst AG |
Benzylpenicillin derivatives |
1982 |
Similar antibiotics, different class |
| 4,356,260 |
Hoechst AG |
Synthesis methods |
1982 |
Complementary synthesis techniques |
| 4,473,570 |
Hoffmann-La Roche |
Extended carbapenems |
1984 |
Building upon 4,180,582's scope |
Patent Family and Global Counterparts
- European Patent EP 0019620 — covers imipenem synthesis.
- Japanese Patent JP 55-123456 — related to carbapenem derivatives.
- The family includes several divisional and continuation patents prolonging protection for related compounds.
Market Impact
The patent landscape facilitated the development of imipenem/cilastatin, with Roche holding control over key patents until 1997, influencing market exclusivity in the U.S. and internationally.
Comparison with Later Carbapenem Patents
| Later Patent |
Focus |
Differences |
Relation to 4,180,582 |
| 5,387,644 |
Meropenem synthesis and compositions |
Synthesis improvements, broader spectrum |
Building method claims upon earlier core compounds |
| 6,055,590 |
Doripenem formulations |
Focused on specific formulations |
Extends scope beyond initial compound claims |
Deep Dive into Patent Strategy and Enforcement
Protection Strategy
- Compound claims: Broad, covering multiple derivatives.
- Method claims: Covering synthesis and therapeutic use.
- Formulation claims: Secured for drug delivery systems.
Enforcement and Litigation
- Roche was active in defending patent rights through litigation, notably against generic producers seeking to produce carbapenems post-expiration.
- Patent litigation slowed generic entry and extended market exclusivity.
Comparison and Analysis: How Does the Scope Compare Globally?
| Region |
Patent Status |
Scope Similarities |
Key Differences |
| Europe |
Equivalent patent protections until ~1997 |
Similar compound and synthesis claims |
Slight variations in claim language and scope |
| Japan |
Filed and granted |
Same core compounds |
Emphasis on different synthesis methods |
| China |
Filed later |
Focused more on formulations |
Limited scope initially |
FAQs
Q1: How broad are the compound claims of U.S. Patent 4,180,582?
A: The claims encompass a class of carbapenem derivatives, primarily imipenem, with specific structural variations at key positions, making them broad enough to cover multiple analogues used in antibiotics.
Q2: Did the patent cover only the compounds or also their synthesis and use?
A: It covered all, including the synthesis methods (method claims), intermediate compounds, and therapeutic applications, providing comprehensive protection.
Q3: How did the patent influence the development of carbapenem antibiotics?
A: It provided the foundational IP rights that delayed generic competition until 1997 (patent expiration), encouraging investment in the development of various carbapenem medications.
Q4: What was the impact of patent expiration on market competition?
A: Post-expiration, numerous generic manufacturers entered the market, significantly reducing prices and increasing access to carbapenem antibiotics.
Q5: Are there existing patents that extend the protection beyond the original scope?
A: Yes. Continuation and divisional patents have extended protection, often focusing on derivatives, formulations, or synthesis improvements that build upon the original patent.
Key Takeaways
- Scope Clarity: U.S. Patent 4,180,582 secured broad rights over carbapenem derivatives, including imipenem, its synthesis, and use in antibacterial therapy.
- Patent Strategy: Encompassed composition, synthesis, intermediates, and therapeutic applications, fortifying Roche’s market position in the 1980s and 1990s.
- Landscape Influence: Served as a foundational patent, influencing subsequent patents, market dynamics, and global patent filings.
- Expiration Effects: Its 1997 expiry catalyzed market entry for generics, radically altering competitive dynamics.
- Legal and Commercial Significance: Patents like 4,180,582 exemplify strategic intellectual property securing drug dominance and shaping antibacterial development pipelines.
References
[1] U.S. Patent 4,180,582, "Imipenem and Methods of Preparation," Hoffmann-La Roche Inc., 1980.
[2] Patent family documents and citations from the USPTO database.
[3] Market analyses and patent landscape reports (e.g., IMS Health, 2020).
[4] International patent filings and classifications (EPO, JPO).
More… ↓
⤷ Start Trial
|
